Rethymic
Payments companies reported to CMS as associated with Rethymic. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Rethymic, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Rethymic
These are the largest totals companies reported as associated with Rethymic. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Daniel Von Hoff | Scottsdale, AZ | Medical Oncology | $25,500.00 |
| Sarah Nicholas | Houston, TX | Allergy & Immunology (Internal Medicine) | $21,280.99 |
| John Sleasman | Durham, NC | Pediatric Allergy/Immunology | $17,332.34 |
| Keith Sacco | Phoenix, AZ | Allergy & Immunology | $15,912.45 |
| Vivian Hernandez-Trujillo | Miami Lakes, FL | Pediatric Allergy/Immunology | $13,097.25 |
| Natalia Chaimowitz | Fort Worth, TX | Allergy & Immunology | $9,597.45 |
| Nikita Raje | Kansas City, MO | Pediatrics | $9,061.20 |
| Christine Seroogy | Madison, WI | Pediatric Allergy/Immunology | $8,447.48 |
| Emmett Mckenzie | Houston, TX | Thoracic Surgery (Cardiothoracic Vascular Surgery) | $7,983.10 |
| Eveline Wu | Chapel Hill, NC | Allergy | $7,795.72 |
Prescribed Rethymic?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.